Minor hallucinations may predict Parkinson’s cognitive decline: Study
The early appearance of minor hallucinations in people with Parkinson’s disease might be a predictor of faster cognitive decline,…
Articles by Andrea Lobo
Cell therapy bemdaneprocel safe in advanced Parkinson’s: Phase 1 trial
Treatment with bemdaneprocel (BRT-DA01), BlueRock Therapeutics’s investigational cell-based therapy, was safe and well tolerated among patients with advanced-stage…
Parkinson’s Foundation expands specialized care network
The Parkinson’s Foundation has expanded its Global Care Network by adding four Centers of Excellence and four Comprehensive…
Potential gene therapy may help with GBA1-linked Parkinson’s
Freeline Therapeutics announced plans to leverage knowledge gained from its FLT201Â gene therapy program in Gaucher disease…
Buntanetap Phase 3 study to move forward after positive safety review
Following a positive safety review, Annovis Bio‘s Phase 3 clinical trial testing oral buntanetap for the treatment of early-stage…
New trial aims to advance research in diseases like Parkinson’s
Koneksa has partnered with Beacon Biosignals to launch a clinical trial focused on advancing research in neuroscience, including…
Enrollment complete in Phase 3 trial of buntanetap for Parkinson’s
Enrollment is now complete for a Phase 3 trial of buntanetap, an oral therapy candidate from Annovis Bio that…
Researchers use worms to study Parkinson’s neurodegeneration
Components from tire wear, higher temperatures and age accelerate the degeneration of dopaminergic neurons in Parkinson’s disease, a new…
Collaboration explores alpha-synuclein in disease-modifying therapies
A collaborative effort between the University of Oxford and Selvita will foster the development of potential disease-modifying therapies targeting…
Real-time brain activity to guide study of personalized light therapy
Neuronic has partnered with Santa Clara University in Silicon Valley to develop a research project to study light…